Dynavax Technologies Corporation (DVAX): Earnings News

DVAX – Misses EPS loss estimates by $0.12 and misses on revenues.

Key Facts Surrounding This News Item

  • DVAX had a POWR Rating of C (Neutral) coming into today.
  • DVAX was 2.95% above its 10-Day Moving Average coming into today.
  • DVAX was 2.86% above its 20-Day Moving Average coming into today.
  • DVAX was 1.97% above its 50-Day Moving Average coming into today.
  • DVAX was -4.62% below its 100-Day Moving Average coming into today.
  • DVAX was 8.65% above its 200-Day Moving Average coming into today.
  • DVAX had returned -5.88% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Dynavax Technologies Corporation (DVAX)

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, using TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company was founded in 1996 and is based in Berkeley, California. View our full DVAX ticker page with ratings, news, and more.

DVAX at a Glance

DVAX Current POWR Rating™
Overall POWR Rating™
DVAX Current Price $12.05 0.33%
More DVAX Ratings, Data, and News

DVAX Price Reaction

The day of this event (Mar. 8, 2018)
DVAX Closing Price$18.00 2.27%
DVAX Volume2,970,000
62.87% from avg
Leading up to this event
DVAX 1-mo return3.53%
After this event
DVAX 1-day return0.28%
DVAX 3-day return7.98%
DVAX 5-day return6.99%

DVAX Price Chart

The Top Stocks For 2019

More Dynavax Technologies Corporation (DVAX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All DVAX News
Page generated in 0.9173 seconds.